In the future, Zhejiang Hisun Pharmaceutical Co.,Ltd will push the developmnet of finished drugs. Now the revenue of finished drugs takes up 20% in total revenue, and the revenue of APIs takes up 80%. Hisun expects the share of finished drugs would increasing to 40% in 5 years. Now Hisun have more than 130 finished drugs, and the key products are anticancer drugs and carbapenem preparations.
The revenue of finished drugs is more than 400 Million Yuan, and next year the expected revenue should be 700 Million Yuan (including taxes). The counstruciton of finished drug base in Fuyang goes well, and the counstruciton will take 2-3 years. By 2009, it's expected that the base should pass the first international certification.
The international compound patent of Fluvastatin will expire in October 2008, so Hisun will try to challenge Fluvastatin's technology patents. If Hisun should get success, Hisun should get new push to its APIs business.